Seagen Inc., a leading biotechnology company headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 1998, Seagen has made significant strides in the oncology sector, particularly in the development of antibody-drug conjugates (ADCs) that target specific cancer cells while minimising damage to healthy tissue. With a strong presence in major operational regions including North America and Europe, Seagen's core products, such as ADCETRIS and PADCEV, are recognised for their unique mechanisms of action and efficacy in treating various types of cancer. The company has established itself as a key player in the biopharmaceutical industry, achieving notable milestones such as FDA approvals and partnerships that enhance its market position. Seagen continues to drive innovation in cancer treatment, aiming to improve patient outcomes worldwide.
We don't have data for Seagen Inc., but we can show you information about their parent organization instead.
View parent company